Arsenal Capital Partners, a private equity firm focused on investing in and building healthcare companies, has made a new $449 million investment in Certara, a drug development software and services company.
Arsenal currently owns approximately 4 percent of common shares outstanding and will acquire approximately 30 million additional shares from funds controlled by EQT Private Equity at $15 per share. At closing, Arsenal will own approximately 22 percent of diluted shares outstanding. Additionally, Arsenal has agreed to a two-year lock-up prohibiting the sale of the newly-purchased shares without company approval. Arsenal previously held a majority stake in the company before selling a controlling interest to EQT in 2017.
“This transaction reflects our long-term advocacy for, and conviction in, the strategic importance of biosimulation in drug development,” comments Stephen McLean, a senior partner of Arsenal. “We look forward to our continued partnership with Certara and to further supporting its efforts to enable more efficacious development of therapies and cures for human disease.”